TITLE

The uphill battle facing antiobesity drugs

AUTHOR(S)
Daubresse, M; Alexander, G C
PUB. DATE
March 2015
SOURCE
International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and orlistat. They also examine the position of the Food and Drug Administration on antiobesity drugs and obesity treatment.
ACCESSION #
101461456

 

Related Articles

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • Two Weight Loss Drugs-Meridia and Xenical The Pros and Cons of Each.  // HealthFacts;Feb2004, Vol. 29 Issue 2, p3 

    Compares weight loss drugs Meridia and Xenical. Details on how the two drugs work; Side effects experienced by users; Costs of the drugs.

  • Weight-Loss Products Found Tainted with Drugs. Klotter, Jule // Townsend Letter;May2009, Issue 310, p23 

    The article focuses on the warning made by the U.S. Food and Drug Administration (FDA) on January 8, 2009 on more than 60 over-the-counter weight-loss products. It is cited that the products lack details on their labels about the active pharmaceutical ingredients that are found in them including...

  • Sibutramine shown the door in the US, Australia, Canada and NZ.  // Reactions Weekly;10/16/2010, Issue 1323, p4 

    The article reports on warnings issued in the U.S., Australia, Canada and New Zealand against the against the continued prescribing and use of the obesity drug sibutramine. According to John Jenkins, of the U.S. Food and Drug Administration (FDA), sibutramine's continued availability is not...

  • SECTION 7 METABOLIC DISORDERS.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p131 

    The article offers information on several drugs for the treatment of obesity. The Belviq weight-loss medication from pharmaceutical firm Eisai Co. Ltd. should be used together with a reduced-calorie diet and weight maintenance to treat obesity. Obese patients are advised to take the Qsymia...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Obesity Drug Qnexa Scores Knockout in EMDAC Bout. Serebrov, Mari // BioWorld Today;2/23/2012, Vol. 23 Issue 36, p1 

    The article reports on the positive support received by Vivus Inc. from the U.S. Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for its weight-loss candidate Qnexa. A Food and Drug Administration approval for Qnexa as a treatment for obesity was recommended by EMDAC via a 20 to 2...

  • FDA Review Spurs Confidence in Qnexa Despite Safety Issues. Young, Donna // BioWorld Today;7/14/2010, Vol. 21 Issue 134, p1 

    This article focuses on the documents released by the U.S. Food and Drug Administration (FDA) about safety issues associated with Qnexa, the obesity pill from Vivus Inc. According to the FDA, the pill has met the 2007 criteria for efficacy in weight loss but there are still concerns over...

  • FDA Approves Lorcaserin for Treatment of Obesity.  // International Cardiovascular Research Journal;2012, Vol. 6 Issue 2, p66 

    The article reports on the approval of lorcaserin by the U.S. Food and Drug Administration (FDA) for the treatment of obesity as of June 2012.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics